Adesuyan, M;
Jani, YH;
Alsugeir, D;
Cheung, ECL;
Chu, CSL;
Howard, R;
Wong, ICK;
(2022)
Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies.
The Journal of Prevention of Alzheimer's Disease
10.14283/jpad.2022.77.
Preview |
Text
Adesuyan_et_al-2022-The_Journal_of_Prevention_of_Alzheimer's_Disease.pdf - Published Version Download (786kB) | Preview |
Abstract
Background Hypertension is a recognized risk factor for dementia. However, evidence for using antihypertensive agents to reduce the risk of Alzheimer’s disease in people with hypertension is inconclusive. Objective To examine the association between antihypertensive agents and the incidence of Alzheimer’s disease in adults with hypertension and normal cognition. Design We conducted a systemic review and performed meta-analyses using Ovid MEDLINE, Ovid Embase, Ovid PsycINFO, Web of science and Scopus, from inception to 18th February 2022. Setting Cohort and case-control studies. Participants Adults ≥ 40 years with hypertension and normal cognition. Intervention Antihypertensive agents. Measurements We performed two separate meta-analyses, pooling the adjusted relative risk (RR) of non-antihypertensive comparator and antihypertensive comparator study design. Results We included nine studies, totalling 1,527,410 individuals. Meta-analysis of non-antihypertensive user comparator studies found that the use of antihypertensive agents is associated with a reduced risk of incident Alzheimer’s disease (RR= 0.94, 95% CI 0.90–0.99; p=0.01). Meta-analysis of antihypertensive comparator studies found evidence that angiotensin II receptor blocker users are associated with a reduction in the risk of Alzheimer’s disease compared to other antihypertensive agents (RR= 0.78, 95% CI 0.68–0.88; p< 0.001). Conclusion Our review provides evidence that the use of antihypertensive agents is associated with a lower incidence of Alzheimer’s disease. The use of angiotensin II receptor blockers may provide the most benefit among antihypertensive agents. Lowering raised blood pressure may not be the only mechanism for cognitive protection and further investigation of the effects of angiotensin II on cognition is indicated.
| Type: | Article |
|---|---|
| Title: | Antihypertensive Agents and Incident Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Observational Studies |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.14283/jpad.2022.77 |
| Publisher version: | https://doi.org/10.14283/jpad.2022.77 |
| Language: | English |
| Additional information: | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
| Keywords: | Alzheimer Disease, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, antihypertensive agents, hypertension |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10156756 |
Archive Staff Only
 |
View Item |
